A collaborative research effort has demonstrated that experimental stem cell therapy can significantly aid recovery from ischemic stroke in mice, according to findings published in Nature Communications. The study was conducted by scientists from the Keck School of Medicine at the University of Southern California, the University of Zurich, and ETH Zurich. Researchers transplanted human-induced pluripotent stem cell-derived neural progenitor cells into mice one week after they suffered ischemic strokes.
These stem cells were developed by reprogramming human blood cells into neural stem cells capable of maturing into different types of neurons. The timing of the intervention was a critical aspect of the study, targeting a post-acute treatment window that would more closely resemble real-world clinical conditions. Five weeks after transplantation, the mice that received the treatment showed marked improvements compared to a control group. The treated mice exhibited reduced inflammation, stronger vascular structures, improved neuronal connectivity, and decreased permeability in the blood-brain barrier.
These outcomes suggest that the transplanted cells contributed to both structural repair and functional recovery in brain tissue damaged by stroke. One of the study’s key findings was the differentiation pathway of the transplanted cells. A significant proportion of the stem cells developed into GABAergic neurons, which are known to regulate neural activity by releasing gamma-aminobutyric acid (GABA). This class of neurons has previously been associated with functional improvements in the post-stroke brain. The predominance of GABAergic neurons among the transplanted cells was linked to enhanced cellular signaling between grafted and host tissues.
GABAergic neurons identified as key players in recovery
Using AI-assisted behavioral analysis tools, the researchers measured functional outcomes in the treated mice. The results indicated complete recovery of fine motor skills and a substantial improvement in gait, highlighting the therapy’s impact on both neurological and physical restoration. Lead author Ruslan Rust, Assistant Professor of Research Physiology and Neuroscience at the Keck School of Medicine, stated that the therapy addresses a significant clinical gap. He noted that a large number of stroke patients are unable to access emergency treatment within the currently recommended timeframe.
The findings point to the potential of post-acute interventions to support recovery even after the initial therapeutic window has closed. The study also identified changes in gene expression related to neuronal growth and repair. The transplanted cells were shown to interact with host tissue through established signaling pathways, including neurexin, neuregulin, and neural cell adhesion molecules. These molecular interactions are consistent with previously documented mechanisms of neuroregeneration and underscore the biological basis for the observed recovery.
Gene expression linked to post-stroke regeneration response
The team is now focusing on further characterizing the long-term behavior of the transplanted cells and refining the molecular mechanisms involved in their integration with host brain tissue. The research is part of a broader investigation into cell-based therapies for neurological conditions involving irreversible brain damage. Ischemic stroke, which occurs when a blood vessel supplying the brain becomes obstructed, remains one of the leading causes of long-term disability worldwide.
Current treatment options are limited by narrow therapeutic windows and are not viable for many patients. The ability to restore neurological function weeks after stroke onset represents a significant advancement in preclinical models. The research was supported by multiple academic institutions and complies with international standards for animal research. While the results are currently limited to preclinical trials, the detailed molecular and functional outcomes offer a foundation for future studies in regulated clinical environments. – By Content Syndication Services.